Business Wire

Avenacy Announces New Product Launches and Participation in DCAT Week 2024

SCHAUMBURG, Ill.--(BUSINESS WIRE)--Avenacy, a specialty pharmaceutical company focused on supplying critical injectable medications, today announced it has launched Fosaprepitant for Injection and ...
Drug Store News

Avenacy launches 2 new generics

Avenacy, a specialty pharmaceutical company focused on supplying injectable medications, has launched Fosaprepitant for Injection and Fulvestrant Injection. “Avenacy has had a strong start to 2024, ...
Business Wire

Dr. Reddy's Laboratories Announces the Launch of Fulvestrant Injection, 250 mg/5 mL (50 mg/mL) per Single-Dose Syringe in the U.S. Market

HYDERABAD, India & PRINCETON, N.J.--(BUSINESS WIRE)--Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today ...
Nasdaq

Capivasertib plus FASLODEX® (fulvestrant) significantly improved progression-free survival vs. FASLODEX in CAPItello-291 Phase III trial in advanced HR-positive breast cancer

Capivasertib, a potential first-in-class AKT inhibitor, combined with FASLODEX could become a new option for patients in this setting regardless of biomarker status WILMINGTON, Del.--(BUSINESS WIRE)-- ...